NovoCure Limited (NVCR) Presents at Morgan Stanley 23rd Annual Global Healthcare

Kelly McCarthy

Good afternoon, everyone, and we appreciate you joining us for a fireside chat with NovoCure. I’m very happy to be joined by CEO, Ashley Cordova. Thanks for coming, Ashley. Hope the conference has been productive for you. I’m Kelly McCarthy. I’m from the Morgan Stanley Healthcare Banking team and really appreciate everyone who’s joining us this afternoon. So I just want to kick off, maybe we can start high level, and you can give an overview of what you’re focused on at NovoCure today.

Ashley Cordova
CEO & Director

Yes. Thank you. So thank you, Kelly, for having me and for the chance to start on. At NovoCure, we have one very clear and simple mission. Together with our patients, we’re striving to extend survival in some of the most aggressive forms of cancer through the development and commercialization of Tumor Treating Fields. So we have one platform therapy, and we are heads down focused on bringing that to as many patients as possible.

Now practically, what does that mean? At this particular phase in company building, we are transitioning from a single indication company with a very significant business in GBM, which generates $600 million in revenue and on its own merits, a significant amount of cash flow to a multi-indication platform. And as we look ahead, exiting 2026, we believe we will have 4 products in hand, a diversified revenue stream across those products and a clear path to profitability.